Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Name:	ocup_CollaborationAndLicenseAgreementAbstract
Namespace Prefix:	ocup_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Milestone payments receivable upon the achievement of development, regulatory and commercial goals.

No definition available.

Name:	ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	ocup_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Milestone payments achieved under the collaboration agreement during the period and recorded as collaboration revenue for the performance obligation.

No definition available.

Name:	ocup_MilestonePaymentAchievedForPerformanceObligation
Namespace Prefix:	ocup_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of milestone payment received upon achieving performance obligation..

No definition available.

Name:	ocup_MilestonePaymentsAmountReceived
Namespace Prefix:	ocup_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Milestone period to administer drug clinical trail of licensed product on first patient in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient
Namespace Prefix:	ocup_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Milestone period to administer drug clinical trail of licensed product on first patient after second indication in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication
Namespace Prefix:	ocup_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Minimum number of countries to conduct development activities.

No definition available.

Name:	ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted
Namespace Prefix:	ocup_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

The amount of non-refundable cash payments received during the period under the collaboration agreement.

No definition available.

Name:	ocup_NonRefundableCashPaymentReceived
Namespace Prefix:	ocup_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of time sales milestone payments eligible to receive based on the achievement of annual sales.

No definition available.

Name:	ocup_NumberOfTimesPaymentsForSalesMilestone
Namespace Prefix:	ocup_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

Percentage of milestone payments eligible to receive on sub-license agreement.

No definition available.

Name:	ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement
Namespace Prefix:	ocup_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

Period of opportunity to cure breach of agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ocup_PeriodOfOpportunityToCureBreachOfAgreement
Namespace Prefix:	ocup_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Period of prior written notice to be served for termination of agreements in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.